SCHEMBL25096871

SCHEMBL25096871

CCc1cc2c(N3CCN(C(=O)OC(C)(C)C)CC3)ccc(Br)c2nn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.44
SMARCA2 P51531 1/20 0.43
SMARCA4 P51532 1/20 0.43
PBRM1 Q86U86 1/20 0.43
BACE1 P56817 5/20 0.43
LMNA P02545 2/20 0.41
CKS1B P61024 2/20 0.41
SKP1 P63208 2/20 0.41
SKP2 Q13309 2/20 0.41
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
GPR119 Q8TDV5 1/20 0.39
MAP4K4 O95819 1/20 0.39
KDM1A O60341 1/20 0.39
KIT P10721 1/20 0.39
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
GBA1 P04062 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30217729 1.00 KCNH2 (0.44) KCNH2SMARCA2SMARCA4PBRM1BACE1
SCHEMBL25097057 0.88 SMARCA2 (0.42) SMARCA2SMARCA4PBRM1BACE1LMNA
SCHEMBL30217772 0.88 SMARCA2 (0.42) SMARCA2SMARCA4PBRM1BACE1LMNA
SCHEMBL30217808 0.86 SMARCA2 (0.41) SMARCA2SMARCA4PBRM1BACE1LMNA
SCHEMBL25097056 0.86 SMARCA2 (0.41) SMARCA2SMARCA4PBRM1BACE1LMNA
SCHEMBL28939509 0.86 LMNA (0.46) KCNH2SMARCA2SMARCA4PBRM1BACE1
SCHEMBL29256995 0.85 RBP4 (0.37) LMNAALDH1A1MAPT
SCHEMBL25096367 0.85 BACE1 (0.46) KCNH2SMARCA2SMARCA4PBRM1BACE1
SCHEMBL30217820 0.85 BACE1 (0.46) KCNH2SMARCA2SMARCA4PBRM1BACE1
SCHEMBL25096995 0.84 SMARCA2 (0.44) KCNH2SMARCA2SMARCA4PBRM1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2024-12-12 US disclosed
CN-118234724-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2024-06-21 CN disclosed
WO-2023034811-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 KCNH2 4745/4885SMARCA2 2493/4885SMARCA4 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.